Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity

Src homology 2 domain-containing phosphatase 2 (SHP2) is an attractive target for cancer therapy due to its multifaceted roles in both tumor and immune cells. Herein, we designed and synthesized a novel series of proteolysis targeting chimeras (PROTACs) using a SHP2 allosteric inhibitor as warhead,...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Jinmin, Bai, Yunpeng, Miao, Yiming, Qu, Zihan, Dong, Jiajun, Zhang, Ruo-Yu, Aggarwal, Devesh, Jassim, Brenson A., Nguyen, Quyen, Zhang, Zhong-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574094/
https://www.ncbi.nlm.nih.gov/pubmed/37836790
http://dx.doi.org/10.3390/molecules28196947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574094/
https://www.ncbi.nlm.nih.gov/pubmed/37836790
http://dx.doi.org/10.3390/molecules28196947

Ejemplares similares